U.S. Markets close in 2 hrs 3 mins
  • S&P 500

    4,150.62
    -37.81 (-0.90%)
     
  • Dow 30

    34,262.26
    -480.56 (-1.38%)
     
  • Nasdaq

    13,378.47
    -23.39 (-0.17%)
     
  • Russell 2000

    2,209.88
    -2.82 (-0.13%)
     
  • Crude Oil

    65.44
    +0.52 (+0.80%)
     
  • Gold

    1,835.20
    -2.40 (-0.13%)
     
  • Silver

    27.68
    +0.19 (+0.68%)
     
  • EUR/USD

    1.2162
    +0.0028 (+0.2311%)
     
  • 10-Yr Bond

    1.6240
    +0.0220 (+1.37%)
     
  • Vix

    21.27
    +1.61 (+8.19%)
     
  • GBP/USD

    1.4160
    +0.0038 (+0.2719%)
     
  • USD/JPY

    108.6090
    -0.2320 (-0.2132%)
     
  • BTC-USD

    56,432.95
    -533.02 (-0.94%)
     
  • CMC Crypto 200

    1,508.51
    +1,265.83 (+521.61%)
     
  • FTSE 100

    6,947.99
    -175.69 (-2.47%)
     
  • Nikkei 225

    28,608.59
    -909.71 (-3.08%)
     

Affimed To Continue Enrollment In AFM13 Lymphoma Study After Positive Interim Data

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Following the Independent Review Committee's assessment, Affimed NV (NASDAQ: AFMDwill continue enrollment in Phase 2 REDIRECT trial evaluating AFM13 as a monotherapy for relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL).

  • The study will continue and combine cohorts of CD30 high and CD30 low expressing PTCL.

  • Preplanned interim futility analysis was conducted in 20 patients in Cohort A (more than 10% of CD30 expression) and Cohort B (CD30 expression between 1% to 10%). The analysis demonstrated that Cohort A's response rate achieved the predefined threshold for the continuation of the study.

  • The response rate in Cohort B was sufficiently comparable to allow the merging of both cohorts into a single cohort.

  • Evidence of anti-tumor response was observed in both cohorts with complete and partial responses.

  • The safety analysis was consistent with previously reported data from Affimed's Phase 1 trials of AFM13, with infusion-related reactions representing the main side effect.

  • Price Action: AFMD shares moved 14.3% higher at $6.25 in premarket trading on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.